- Home
- Applications
- clinical candidate developed
Show results for
Refine by
Clinical Candidate Developed Product Applications
17 applications found
BOC Sciences is committed to supplying cost-effective products and services. We provide Choline Fenofibrate (Cas No:856676-23-8). More information, please visit the website: http://www.bocsci.com/choline-fenofibrate-cas-856676-23-8-item-84-259938.html ...
ByBOC Sciences based in Shirley, NEW YORK (USA)
Prancer RTSM provides the flexibility you need to explore all the possible paths for determining the optimal dose, patient population, and combination therapies within your Phase 2 ...
By4G Clinical based in Wellesley, MASSACHUSETTS (USA)
4C Supply leverages available information to develop an initial supply plan for IP production and combination therapy procurement. From as early as 1-3 years before you enter Phase 1, 4C Supply® is a critical tool for developing and maturing your supply planning and manufacturing needs. ...
By4G Clinical based in Wellesley, MASSACHUSETTS (USA)
Site satisfaction is a top priority at 4G Clinical. Prancer RTSM® was designed with direct site feedback, ensuring researchers are able to spend more time with their patients and less time worrying about ...
By4G Clinical based in Wellesley, MASSACHUSETTS (USA)
As of late, mobile applications have administered the computerized world and changed individual's method of living. These days clinical application improvement organizations have modernized the manner in which the people keep up their wellness, medical clinics analyze their patients, wellbeing reports are being sent. For all the clinics the executives, social insurance authorities, patients, physicists and so forth. Moon Technolabs offers extraordinary human services application development and arrangements. ...
ByMoon Technolabs based in Ahmedabad, INDIA
Comprehensive antibody reactivity profiling: validate specificity, identify cross-reactions. The issue of antibody cross-reactivity is one that has often been often overlooked or sidelined in the past, with typical antibody QC involving evidence of binding to the intended target, while neglecting potential cross-reactivity. In recent years, however, many examples have come to light where poor validation of antibodies has led to misleading or erroneous conclusions for assays in which they are used as reagents, due ...
ByCambridge Protein Arrays Ltd. (CPAP) based in Cambridge, UNITED KINGDOM
Our platform delivers investigational medicinal products that contain diverse and viable communities of donor-derived microorganisms that target multiple functional pathways. We believe that this approach is superior to others being pursued and provides the company with numerous competitive advantages, including: de-risking of clinical programmes based on IMT precedence, accelerated clinical development and opportunities to discover second and third generation products through data generated from clinical ...
ByEnteroBiotix Ltd based in Glasgow, UNITED KINGDOM
Our product pipeline shows the progress we’re making on clinical programs currently in development to create mRNA medicines for a wide range of diseases and conditions. We are proud of the advancements we’ve made in pioneering new mRNA vaccines and treatments that may have the potential to treat and prevent rare ...
ByModerna, Inc. based in Cambridge, MASSACHUSETTS (USA)
Our driving philosophy at Otsuka is to serve those with unmet medical needs, and that couldn’t be more true than in our dedication to the central nervous system (CNS) space. In our 30 years of experience working in this therapeutic area, we continue to innovate and defy limitation by taking risks to overcome the complexities of treating mental health. We respect the value within every mind and are committed to making a difference in the lives of patients living with schizophrenia, major depressive disorder, ...
ByOtsuka America Pharmaceutical, Inc based in Princeton, NEW JERSEY (USA)
Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. ...
ByFinch Therapeutics Group, Inc. based in Somerville, MASSACHUSETTS (USA)
From AI innovation in emergency medicine to cardiology, Centaur Labs provides researchers on the cutting edge of their fields with high-quality medical data annotations at unprecedented speed and ...
ByCentaur Labs based in Boston, MASSACHUSETTS (USA)
The use of probiotics is a very promising alternative for the prevention and/or treatment of multiple health issues, in both humans and animals. By modifying the composition of the microbiota with probiotics, we may help to mitigate and solve upper respiratory, genitourinary or gastrointestinal tracts and periodontal infections, as well as dysbiosis issues related to fertility, premature births, dermatology, autoimmune diseases, and many more. The key is to choose the appropriate strain and dosage for each ...
ByZinereo Pharma based in Pontevedra, SPAIN
2A Pharma’s vaccine platform is based on mutated parvoviral particles consisting essentially of one protein. The particles contain no viral genome and are replicative defective and non-pathogenic. The particle capsid surface has repetitive, immunogenic sites, where peptides of interest can be inserted and allows us to generate monovalent or bivalent vaccines as required. Each peptide of interest will be presented 60 times on the capsid surface and both the innate and adaptive immune systems are activated to ...
By2A Pharma ApS based in Aalborg Øst, DENMARK
Gastric cancer is a disease in which cancer cells form in the lining of the stomach. Almost all gastric cancers are adenocarcinomas, a cancer that begins in glandular tissue. Gastric cancer is often in an advanced stage when it is diagnosed. At this stage, it can often be treated, but rarely ...
ByAscelia Pharma AB based in Malmö, SWEDEN
From accelerating drug discovery to leveraging real world evidence, Centaur Labs provides life sciences innovators with high-quality medical data annotations at unprecedented speed and ...
ByCentaur Labs based in Boston, MASSACHUSETTS (USA)
Our First DCGI Approved Stem Cell Product: Stempeucel® is the FIRST innovative stem cell based biological product to be approved by DCGI (Indian FDA) for manufacturing and marketing for the treatment of Critical Limb Ischemia (CLI). Stempeucel® product has been licensed to Cipla in India. Stempeutics is seeking partnership for further clinical development and commercialization of Stempeucel® for Global ...
ByStempeutics Research Pvt. Ltd. based in Bangalore, INDIA
The antibody drug discovery process differs from the traditional drug discovery of small molecules as it requires the development of hybridomas and the engineering of antibodies to recognize a specific target protein. The production of recombinant antibodies in cancer treatment as well as the development of neutralizing antibodies for infectious diseases, has allowed antibody discovery platforms to interrogate the immune repertoire and develop novel antibody libraries using flow cytometry analysis and cell ...
ByNanoCellect Biomedical, Inc. based in San Diego, CALIFORNIA (USA)